NASDAQ · Biotechnology

Dermata Therapeutics, Inc. (DRMA) Stock

$1.02 -4.67% NASDAQ: DRMA Healthcare

Valuation

MetricValue
Price$1.02
Market Cap$4.10M
P/E Ratio-0.25
P/B Ratio1.27
P/S Ratio0.00
EPS (TTM)$-8.16
52-Week High$5.87
52-Week Low$0.95
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-166.67%
ROA-157.28%
ROCE-246.61%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-8.0M$-10.0M$-8.0M$-13.0M$-8.0M
Net Profit$-8.0M$-10.0M$-8.0M$-12.0M$-8.0M
EPS$-152.70$-2088.00$-399.81$-80.32$-8.16
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$12.0M$7.0M$8.0M$4.0M$8.0M
Total Liabilities$2.0M$1.0M$2.0M$2.0M$2.0M
Cash$11.0M$6.0M$7.0M$3.0M$8.0M
Borrowings$0$0$0$0$0

Latest News

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 ACCESS Newswire · May 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-6.0M$-9.0M$-6.0M$-11.0M$-8.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$10.0M$-5.0M$1.0M$-4.0M$4.0M
Free Cash Flow$-6.0M$-9.0M$-6.0M$-11.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.00
FCF Yield-183.26%
Quick Ratio2.73
Interest Coverage0.00
Return 1Y-82.19%
Return 3Y-99.45%
Return 5Y—

Ownership

Insiders Held24.82%
Institutions Held7.38%
Institutions Float Held9.81%
Institutional HolderSharesReport Date
Geode Capital Management, LLC48,3342026-03-31
UBS Group AG35,6082026-03-31
Welch & Forbes, LLC20,0002026-03-31
MCF Advisors LLC1,7322026-03-31
Tower Research Capital LLC (TRC)7162026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTLArtelo Biosciences, Inc. $3.26 -3.26% -0.05 $1.26M 0.00%
ATXIAvenue Therapeutics, Inc. $0.26 -32.94% -0.49 $856691 0.00%
CARMCarisma Therapeutics, Inc. $0.01 -5.17% 0.01 $230148 0.00%
ELABPMGC Holdings Inc. $3.08 -1.60% 0.00 $1.40M 0.00%
GTBPGT Biopharma, Inc. $6.68 +12.08% -0.06 $8.43M 0.00%

About Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. is led by CEO Gerald T. Proehl, employs 8 people, headquartered in US, publicly traded since 2021.

Dermata Therapeutics, Inc. (DRMA) stock trades at $1.02 with a market capitalization of $4.10M. The stock is valued at a price-to-earnings (P/E) ratio of -0.25, price-to-book of 1.27, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.95 and $5.87, and currently trades 82.6% below its 52-week high.

On profitability, Dermata Therapeutics, Inc. generates a return on equity (ROE) of -166.67%, return on capital employed of -246.61%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides